Breast cancer (BC) is the second most common cause of cancer-related deaths in women worldwide. The availability of reliable biomarkers of response/resistance to cancer treatments would benefit patients and clinicians allowing for a better selection of BC patients most likely to respond to a specific treatment. Phosphatidylinositol 3-kinase (PI3K) enzymes are involved in numerous cellular- functions and processes. The gene encoding for PI3K catalytic subunit p110α is mutated in 20-40% of BC. We performed a meta-analysis of the current literature on randomized clinical trials, investigating the role of PIK3CA mutational status as prognostic factor, and predictor of response to anti-cancer treatments. Overall 1929 cases were included. The pooled analysis confirmed that the presence of a PIK3CA mutation represents an independent negative prognostic factor (HR = 1.67, 95%CI: 1.15-2.43; P = 0.007) in BC, as previously reported. As PI3K signaling is also a result of other pathways' hyperactivation, further investigation of potential biomarkers able to predict likelihood of response to anti-PI3K/mTOR, anti-HER2, and other TKRs is warranted in future randomized clinical trials.

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis / Sobhani, Navid; Roviello, Giandomenico; CORONA, SILVIA; Scaltriti, Maurizio; Ianza, Anna; Bortul, Marina; Zanconati, Fabrizio; Generali, Daniele. - In: JOURNAL OF CELLULAR BIOCHEMISTRY. - ISSN 0730-2312. - STAMPA. - 119:(2018), pp. 4287-4292. [10.1002/jcb.26687]

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis

Roviello, Giandomenico;
2018

Abstract

Breast cancer (BC) is the second most common cause of cancer-related deaths in women worldwide. The availability of reliable biomarkers of response/resistance to cancer treatments would benefit patients and clinicians allowing for a better selection of BC patients most likely to respond to a specific treatment. Phosphatidylinositol 3-kinase (PI3K) enzymes are involved in numerous cellular- functions and processes. The gene encoding for PI3K catalytic subunit p110α is mutated in 20-40% of BC. We performed a meta-analysis of the current literature on randomized clinical trials, investigating the role of PIK3CA mutational status as prognostic factor, and predictor of response to anti-cancer treatments. Overall 1929 cases were included. The pooled analysis confirmed that the presence of a PIK3CA mutation represents an independent negative prognostic factor (HR = 1.67, 95%CI: 1.15-2.43; P = 0.007) in BC, as previously reported. As PI3K signaling is also a result of other pathways' hyperactivation, further investigation of potential biomarkers able to predict likelihood of response to anti-PI3K/mTOR, anti-HER2, and other TKRs is warranted in future randomized clinical trials.
2018
119
4287
4292
Sobhani, Navid; Roviello, Giandomenico; CORONA, SILVIA; Scaltriti, Maurizio; Ianza, Anna; Bortul, Marina; Zanconati, Fabrizio; Generali, Daniele
File in questo prodotto:
File Dimensione Formato  
Sobhani_et_al-2018-Journal_of_Cellular_Biochemistry.pdf

Accesso chiuso

Dimensione 487.04 kB
Formato Adobe PDF
487.04 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1156786
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 66
  • ???jsp.display-item.citation.isi??? 58
social impact